Purpose: To investigate the correlation between epidermal growth factor (EFG) and atrophic glossitis (AG) in patients with Sjoigren's syndromes (SS) and explore its pathogenesis.
Methods: Ninety-three patients with SS (60 with AG and 33 without AG) and 20 normal were selected. The concentrations of EGF in saliva were analyzed by ELISA. The expressions of EGF receptor (EGFR) in the epithelial cells of the tongue were assayed by immunohistochemistry. The differences among each group were analyzed with SPSS19.0 software package.
Results: The saliva EGF concentrations in SS was lower than that in normal control group(P<0.0001),and EGF concentrations in SS with AG was significantly lower than that in SS without AG (P=0.024). EGF levels in saliva gradually decreased in the mild, moderate and severe atrophic glossitis groups, and there were significant differences among each group(P<0.05). EGFR in the epithelial cells of tongue was lower in SS with moderate and severe AG than in the control group(P=0.009, P=0.037), and there was a significant correlation between EGF and the degree of AG (r=-0.673, P<0.01).
Conclusions: Saliva EGF concentrations decrease significantly in patients with SS and it is closely related to the morbidity of atrophic glossitis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Receptor discordance after nipple-sparing mastectomy.
Surg Pract Sci
June 2024
Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
Background: Recent studies have shown that receptor status of breast cancer change between primary tumor and recurrence, which may influence treatment strategy and prognosis, but there are few reports on receptor discordance between primary tumors and local recurrence (LR) after nipple-sparing mastectomy (NSM).
Patients And Methods: We collected 74 patients who had LR after NSM for newly diagnosed stages 0 to 3 breast cancer between 2008 and 2016 at 14 institutions. We classified into 4 subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2).
Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight.
Drugs
January 2025
Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK.
The incidence of gastroesophageal cancers is rising, driven, in part, by an increasing burden of risk factors of obesity and gastroesophageal reflux. Despite efforts to address these risk factors, and a growing interest in methods of population screening, the bulk of these tumours are unresectable at diagnosis. In this setting, effective systemic treatments are paramount to improve survival and quality of life.
View Article and Find Full Text PDFHER2 Status in Gastric and Gastroesophageal Carcinomas: Evaluation of Histopathological Fingings, Paired ResectionBiopsy Specimens, and the Effect of Neoadjuvant Therapy: A Single Center Study.
Turk J Gastroenterol
January 2025
Department of Medical Pathology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Background/aims: Accurately determining the human epidermal growth factor receptor 2 (HER2) status is crucial in identifying suitable candidates for targeted therapy in gastric cancer, considering the cost and potential side effects of anti-HER2 treatments. This study aimed to assess HER2 overexpression/amplification prevalence in gastric and gastroesophageal cancer patients, its correlation with clinicopathological characteristics, and the consistency of HER2 status between biopsy and radical specimens.
Materials And Methods: We analyzed data from 667 specimens of 600 gastric/gastroesophageal cancer patients at Dokuz Eylül University Faculty of Medicine from 2012 to 2021.
Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer.
EMBO J
January 2025
Department of Colorectal Surgery and Oncology and Department of Cell Biology, Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Distant metastasis is the major cause of gastric cancer mortality, and epidermal growth factor receptor (EGFR) activation plays critical roles in gastric cancer dissemination. However, EGFR targeting therapies in gastric cancer show only marginal effects, and the molecular mechanisms of oncogenic EGFR signaling remain poorly defined. Here, we report Ephrin A1 as a novel ligand of EGFR in gastric cancer.
View Article and Find Full Text PDFUsing the AP1 Transcription Factor FOSL1 to Assess the Exacerbation of Psoriasis.
Curr Mol Med
January 2025
Laboratory of Physicochemical and Genetic Problems in Dermatology, Center of Theoretical Problems in Physico-Chemical Pharmacology at Russian Academy of Sciences, Moscow Russia.
Background: The transcription factor AP1 plays a crucial role in the proliferation, apoptosis, and terminal differentiation of epidermal keratinocytes.
Objective: This study aimed to clarify whether the subunit of AP1, FOSL1 protein, can be used to assess the exacerbation of psoriasis by evaluating its changes in protein and mRNA levels in cultured epidermal keratinocytes and skin specimens of the patients prescribed with bathwater PUVA (Psoralen and UVA) therapy. This study aimed to investigate FOSL1, a subunit of the transcription factor AP-1, as a potential biomarker for psoriasis by examining its protein and mRNA expression in skin specimens from patients undergoing bathwater PUVA (Psoralen and UVA) therapy and cultured epidermal keratinocytes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!